Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CNR2 | P34972 | 1/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 2/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.68 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Arachidonoylglycerol SCHEMBL3685146 | 1.00 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL136278 | 1.00 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| 2-Arachidonoylglycerol SCHEMBL18062264 | 1.00 | FAAH (1.00) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL29575039 | 0.98 | FAAH (0.97) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL4248585 | 0.97 | FAAH (0.94) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL23782661 | 0.95 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL145068 | 0.95 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL29582801 | 0.95 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL30863743 | 0.95 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 | |
| SCHEMBL4572639 | 0.95 | MAPT (0.91) | FAAHMAPTALDH1A1HPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5169 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4734961-A1 | NEW METHOD OF PRODUCING AN AQUEOUS MESOPARTICLE COMPOSITION COMPRISING A LIPOPHILIC COMPOUND | BIOGNTX R&D B.V. (NL) | 2026-05-06 | — | — | EP | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724052-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMIPLEGIC MIGRAINE | Schedule 1 Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097051-A1 | CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| EP-4713314-A1 | A BINDING SITE TO PREVENT ENDOCANNABINOID CELLULAR REUPTAKE | Universität Bern (CH) | 2026-03-25 | — | — | EP | claimed |
| US-20260069616-A1 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE | SCHEDULE 1 THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-20260074041-A1 | METHODS OF TREATMENT AND INTERVENTIONS FOR IMPROVING OR MAINTAINING HEALTH AND WELLNESS BASED ON QUANTITATIVE ASSESSMENT OF BIOMARKER LEVELS | MATTER NEUROSCIENCE INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049977-A1 | CELL-BASED ASSAY FOR QUANTIFYING THE POTENCY AND EFFICACY OF CANNABINOIDS AND/OR TERPENOIDS, AND METHODS OF USE THEREOF | CANNAMETRIX LLC (US) | 2026-02-19 | — | — | US | claimed |
| US-20020062099-A1 | Adsorbent, adsorbing and removing process and adsorber for endogenous cannabinoid | KANEKA CORPORATION (JP) | 2002-05-23 | — | — | US | claimed |
| US-20020045157-A1 | Adsorbent, adsorbing and removing process and adsorber for endogenous cannabinoid | KANEKA CORPORATION (JP) | 2002-04-18 | — | — | US | claimed |
| EP-1192977-A1 | Adsorbent, adsorbing and removing process and adsorber for endogenous cannabinoid | Kaneka Corporation (JP) | 2002-04-03 | — | — | EP | claimed |
| EP-1181977-A1 | Adsorbent, adsorbing and removing process and adsorber for endogenous cannabinoid | Kaneka Corporation (JP) | 2002-02-27 | — | — | EP | claimed |
| US-20020019444-A1 | Anandamide and structurally related lipids as vanilloid receptor modulators | HOGESTATT EDWARD (SE) | 2002-02-14 | — | — | US | claimed |
| WO-2002012549-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCEROL METABOLITES | VANDERBILT UNIVERSITY (US) | 2002-02-14 | — | — | WO | claimed |
| WO-2001097793-A2 | 2-ARACHIDONYLGLYCEROL (2-AG) - AN INHIBITOR OF TUMOR NECROSIS FACTOR -ALFA AND NEUROPROTECTOR OF BRAIN IN CLOSED HEAD INJURY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-12-27 | — | — | WO | claimed |
| WO-2001085158-A2 | ANANDAMIDE AND STRUCTURALLY RELATED LIPIDS AS VANILLOID RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2001-11-15 | — | — | WO | claimed |
| WO-2001028588-A1 | CANNABINOIDS AS VASODILATORS AND CARDIOPROTECTORS AGAINST ISCHEMIA | UNIVERSITE DE MONTREAL (CA) | 2001-04-26 | — | — | WO | claimed |
| WO-2001001980-A1 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-11 | — | — | WO | claimed |